
The biggest piece of Mars on Earth is going up for auction in New York
NEW YORK — For sale: A 54-pound (25-kilogram) rock. Estimated auction price: US$2 million to $4 million. Why so expensive? It's the largest piece of Mars ever found on Earth.
Sotheby's in New York will be auctioning what's known as NWA 16788 on Wednesday as part of a natural history-themed sale that also includes a juvenile Ceratosaurus dinosaur skeleton that's more than six feet (two metres) tall and nearly 11 feet (three metres) long.
According to the auction house, the meteorite is believed to have been blown off the surface of Mars by a massive asteroid strike before traveling 140 million miles (225 million kilometres) to Earth, where it crashed into the Sahara. A meteorite hunter found it in Niger in November 2023, Sotheby's says.
The red, brown and gray hunk is about 70 per cent larger than the next largest piece of Mars found on Earth and represents nearly seven per cent of all the Martian material currently on this planet, Sotheby's says. It measures nearly 15 inches by 11 inches by six inches (375 millimetres by 279 millimetres by 152 millimetres).
'This Martian meteorite is the largest piece of Mars we have ever found by a long shot,' Cassandra Hatton, vice chairman for science and natural history at Sotheby's, said in an interview. 'So it's more than double the size of what we previously thought was the largest piece of Mars.'
It is also a rare find. There are only 400 Martian meteorites out of the more than 77,000 officially recognized meteorites found on Earth, Sotheby's says.
Hatton said a small piece of the red planet remnant was removed and sent to a specialized lab that confirmed it is from Mars. It was compared with the distinct chemical composition of Martian meteorites discovered during the Viking space probe that landed on Mars in 1976, she said.
The examination found that it is an 'olivine-microgabbroic shergottite,' a type of Martian rock formed from the slow cooling of Martian magma. It has a course-grained texture and contains the minerals pyroxene and olivine, Sotheby's says.
It also has a glassy surface, likely due to the high heat that burned it when it fell through Earth's atmosphere, Hatton said. 'So that was their first clue that this wasn't just some big rock on the ground,' she said.
The meteorite previously was on exhibit at the Italian Space Agency in Rome. Sotheby's did not disclose the owner.
It's not clear exactly when the meteorite hit Earth, but testing shows it probably happened in recent years, Sotheby's said.
The juvenile Ceratosaurus nasicornis skeleton was found in 1996 near Laramie, Wyoming, at Bone Cabin Quarry, a gold mine for dinosaur bones. Specialists assembled nearly 140 fossil bones with some sculpted materials to recreate the skeleton and mounted it so it's ready to exhibit, Sotheby's says.
The skeleton is believed to be from the late Jurassic period, about 150 million years ago, Sotheby's says. It's auction estimate is $4 million to $6 million.
Ceratosaurus dinosaurs were bipeds with short arms that appear similar to the Tyrannosaurus rex, but smaller. Ceratosaurus dinosaurs could grow up to 25 feet (7.6 metres) long, while the Tyrannosaurs rex could be 40 feet (12 metres) long.
The skeleton was acquired last year by Fossilogic, a Utah-based fossil preparation and mounting company.
Wednesday's auction is part of Sotheby's Geek Week 2025 and features 122 items, including other meteorites, fossils and gem-quality minerals.
Collins reported from Hartford, Connecticut.
Dave Collins And Joseph B. Frederick, The Associated Press

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


National Post
5 hours ago
- National Post
Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)
Article content Article content Article content CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced positive results in a preclinical, exposure-based therapeutic model for post-traumatic stress disorder (PTSD). Article content In fear conditioned mice, oral administration of EB-003 significantly decreased context-induced freezing behavior when measured one-hour post-dose (p < 0.05) indicating a positive therapeutic effect with extinction of contextual fear after a single dose. These results were in line with the therapeutic effects observed with MDMA, which was used as a positive control in this study. MDMA is a psychedelic controlled substance that has demonstrated clinical benefit in the treatment of PTSD in human trials, although it is not approved by the FDA. Article content The pairing of electrical shock stimulus with a controlled environment generates context-based traumatic memories leading to freezing behaviors when the subject is re-exposed to the same environment. This well-established translational rodent model, performed by a third-party lab, is designed to induce a potent, trauma-related state of fear using a Pavlovian association paradigm. Article content 'Only a few medications have been approved by the FDA for the treatment of PTSD, including the serotonin reuptake inhibitors (SSRIs) paroxetine and sertraline,' said Joseph Tucker, Ph.D., CEO and Director of Enveric. 'Only 20% to 30% of PTSD patients experience full remission with these drugs and it takes two to three weeks of SSRI administration before clinical and neuronal benefits become apparent. Clearly, there is enormous unmet need in PTSD, which has yet to be addressed with meaningful innovation.' Article content Dr. Tucker added: 'Research has implicated impaired hippocampal neuroplasticity as key underlying features of patients struggling with PTSD. We are very encouraged that a single dose of our lead neuroplastogen, EB-003, facilitated rapid fear extinction in mice.' Article content In light of this new data, EB-003, a next-generation neuroplastogen that may enhance hippocampal neuroplasticity without causing hallucinations, has the potential to significantly improve treatment outcomes for this chronic and debilitating mental health condition, representing a major opportunity in an underserved market. Article content About Enveric Biosciences Article content Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development Psybrary™ platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit Article content Forward-Looking Statements Article content This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. Article content A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Article content Article content Article content Article content Article content Contacts Article content Investor Relations Tiberend Strategic Advisors, Inc. David Irish (231) 632-0002 dirish@ Article content


National Post
6 hours ago
- National Post
AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention
Article content Article content for the over one million cardiac surgery patients globally without a preoperative Afib diagnosis Article content MASON, Ohio — AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the completion of enrollment in the left atrial appendage exclusion for prophylactic stroke reduction (LeAAPS) clinical trial (NCT05478304). Initiated in January 2023, LeAAPS enrolled 6,500 patients across 137 centers globally. Article content LeAAPS is a prospective, randomized, blinded, superiority, investigational device exemption (IDE) trial evaluating the AtriClip ® LAA Exclusion System for the prevention of ischemic stroke and systemic arterial embolism in cardiac surgery patients without a history of Afib—a large and often underserved population at elevated risk for these events. It is estimated that well over one million cardiac surgery procedures occur annually and more than 70% of these patients have no history of Afib before surgery. Article content 'The LeAAPS trial is a bold clinical evidence initiative that demonstrates AtriCure's unwavering commitment to improving care for cardiac surgery patients,' said Michael Carrel, President and CEO of AtriCure. 'The rapid pace of trial enrollment is a testament to the exceptional team of clinical trial investigators and broader clinician interest in changing the standard of care in cardiac surgery. LeAAPS presents an incredible opportunity to drive improved long-term outcomes for patients while significantly expanding our market leadership through the increased use of our AtriClip devices.' Article content Results of AtriCure's LeAAPS trial are expected to inform clinical practice and treatment guidelines for stroke prevention, using AtriClip platform technology, in patients undergoing planned cardiac surgery. The trial will continue with five years of follow-up to assess long-term outcomes. LeAAPS is being conducted in collaboration with the Population Health Research Institute (PHRI), affiliated with McMaster University in Hamilton, Ontario. PHRI brings extensive experience in designing and executing large-scale international clinical trials. Article content 'For decades, the medical community has sought to better understand the role of the LAA in stroke following cardiac surgery,' said Dr. Richard Whitlock, Cardiothoracic Surgeon at McMaster University and Global Principal Investigator for the trial. 'LeAAPS aims to deliver definitive evidence to guide optimal care for high-risk patients without Afib who may benefit from LAA exclusion.' Article content AtriCure first entered the LAA management market with FDA 510(k) clearance of the AtriClip System in 2010. Today, AtriClip devices are the most widely used LAA management device worldwide. The company plans to use LeAAPS data to support an expanded indication for stroke prevention in patients at elevated risk of ischemic stroke. Article content About AtriCure Article content AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure's Isolator ® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent and long-standing persistent Afib. AtriCure's AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE ® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit or follow us on X @AtriCure. Article content Forward-Looking Statements Article content Certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Actual results may differ materially from those projected by any forward-looking statements. These risks and uncertainties include, but are not limited to, the following: our estimate of the market for our products; the rate and degree of market acceptance of our products; negative clinical data, including data that does not demonstrate sufficient safety and efficacy with respect to our products; the timing of and ability to obtain and maintain regulatory clearances and approvals for our products; our ability to comply with extensive FDA regulations; the timing of and ability to obtain third party payor reimbursement of procedures utilizing our products; the impact of tariffs or other restrictive trade measures; and litigation, administrative or other proceedings. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ('SEC'), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 14, 2025, and our quarterly reports on Form 10-Q. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change. Article content Article content Article content Article content Article content Contacts Article content

National Post
6 hours ago
- National Post
MilliporeSigma Launches AAW™ Workstation to Advance Lab Automation
Article content New platform powered by Opentrons expands lab automation to accelerate scientific discovery Plug-and-play design for effortless integration into diverse laboratory settings Validated protocols across applications benefit academia, pharma, and biotech Article content BURLINGTON, Mass. — MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched the AAW™ Automated Assay Workstation, a solution powered by Opentrons, a leader in lab automation and accessible robotics. The workstation automates routine laboratory experiments previously performed manually, reducing hands-on time and ensuring consistency in results across diverse experimental settings. This launch follows the earlier announcement of a multi-year partnership with Opentrons Labworks, Inc. to enhance laboratory workflows through automation. Article content 'The AAW™ Workstation exemplifies our commitment to equipping scientists with solutions that simplify their workflows and enhance their research capabilities.' 'Our customers are increasingly seeking tools that improve efficiency and deliver reliable and reproducible results,' said Anand Nambiar, Head of Science & Lab Solutions, Life Science business of Merck KGaA, Darmstadt, Germany. 'The AAW™ exemplifies our commitment to equipping scientists with solutions that simplify their workflows and enhance their research capabilities. By automating routine tasks, researchers can focus on solving complex scientific challenges and accelerate discovery.' Article content Designed to advance the lab of the future, the AAW™ offers a plug-and-play setup and an extensive library of validated assay protocols across protein, molecular, and cell biology applications. Its versatility and ease of integration make it an ideal fit for academic, biotech, and pharmaceutical labs looking to boost productivity without compromising quality. Article content The AAW™ joins MilliporeSigma's growing portfolio of digital and automation innovations, including: Article content For more information about the AAW™ and to explore our full range of innovative solutions, visit Article content The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 26,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics. Article content Around 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. Article content The company holds the global rights to the name and trademark 'Merck' internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit Article content All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service. Article content About Opentrons Article content Opentrons Labworks, Inc., a disruptive life science company and the current market leader in entry-level lab automation, accelerates innovation in research and healthcare through its integrated lab platform, which includes business units Opentrons ® Robotics and Neochromosome™. Opentrons has raised over $200 million in funding and achieved unicorn status based on its innovative technologies. The Opentrons Flex ® is Opentrons' newest generation of liquid-handling lab robots, offering open-source accessibility and compatibility with generative AI tools. Opentrons Robotics provides thousands of institutions with flexible, easy-to-use lab robots, automating R&D operations and making robotics, a vast open-source library accessible to life sciences researchers worldwide. Opentrons is used in labs at the top 20 academic universities in the US and 14 of 15 leading global biopharmaceutical companies. Learn more at Article content Article content Article content Contacts Article content Article content